<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669119</url>
  </required_header>
  <id_info>
    <org_study_id>2020/6422</org_study_id>
    <nct_id>NCT04669119</nct_id>
  </id_info>
  <brief_title>Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.</brief_title>
  <official_title>Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Thiamine, Riboflavin, Pyridoxine, Vitamin D, Superoxide Dismutase on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy: Blinded Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari Aldo Moro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari Aldo Moro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: to investigate the effects of dietary supplements on postoperative edema and pain in&#xD;
      patients undergoing quadrantectomy for breast cancer.&#xD;
&#xD;
      Methods: 120 patients will be randomized into 3 groups: A, treated with Bromelain/Boswellia&#xD;
      Serrata Casperome and Centella Asiatica with Vitamins for 30 days; B, treated with&#xD;
      Bromelain/Bosswellia Serrata and placebo for 30 days; C, treated with 2 placebos. Inclusion&#xD;
      criteria: adult (&gt;18 years) patients with breast cancer undergoing quadrantectomy with or&#xD;
      without sentinel lymph node biopsy. Exclusion criteria: diabetic neuropathy, previous&#xD;
      breast/chest surgeries, allergies to studied drugs, severe kidney failure, alcohol and toxics&#xD;
      addiction, axillary lymphadenectomy. Patients will be studied through ultrasound examination&#xD;
      for edema and collections, VAS and DN4 for pain, during 30 postoperative days. Patients will&#xD;
      also be studied through psychological and physiatric evaluations. Wilcoxon, T student,&#xD;
      Chi-Squared tests will be used to evaluate the outcomes. STATA 14 (StataCorp LP, College&#xD;
      Station, Tex, USA) will be used for the analysis. P&lt;0.05 will be statistically significant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postoperative normalized echogenicity of breast and subcutaneous tissue from the first to the 30th day after quadrantectomy with or without sentinel lymph node biopsy</measure>
    <time_frame>30 days</time_frame>
    <description>Ultrasound measured postoperative edema, obtained through the evaluation of normalized echogenicity, of breast and subcutaneous tissue after quadrantectomy with or without sentinel lymph node biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with postoperative fluid collections in the breast and or subcutaneous tissue during 30 days after quadrantectomy with or without sentinel lymph node biopsy</measure>
    <time_frame>30 days</time_frame>
    <description>Ultrasound measured postoperative collections of breast and subcutaneous tissue after quadrantectomy with or without sentinel lymph node biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postoperative pain measured daily through VAS (visual analogue scale) from the first to the 30th day after quadrantectomy with or without sentinel lymph node biopsy</measure>
    <time_frame>30 days</time_frame>
    <description>VAS (visual analogue scale) from 0 (absence of pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postoperative probability of neuropathic pain measured daily through DN4 (Douleur Neuropathique en 4 Questions) from the first to the 30th day after quadrantectomy with or without sentinel lymph node biopsy</measure>
    <time_frame>30 days</time_frame>
    <description>DN4 (Douleur Neuropathique en 4 Questions) from 0 (low probability of neuropathic pain) to 10 (high probability of neuropathic pain)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated post-operatively for 30 days with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bromelain/Boswellia Serrata Casperome</intervention_name>
    <description>Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton</description>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins</arm_group_label>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Centella Asiatica/Vitamins</intervention_name>
    <description>Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton</description>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Bromelain/Boswellia Serrata Casperome and placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;18 years) with breast cancer undergoing quadrantectomy with or&#xD;
             without sentinel lymph node biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetical neuropathy&#xD;
&#xD;
          -  Previous breast/chest surgery&#xD;
&#xD;
          -  Allergies to studied drugs&#xD;
&#xD;
          -  Severe kidney failure&#xD;
&#xD;
          -  Alcohol and toxics addiction&#xD;
&#xD;
          -  Axillary lymphadenectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Gurrado, Prof</last_name>
      <phone>00390805595092</phone>
      <email>ruggierodimonte@yahoo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari Aldo Moro</investigator_affiliation>
    <investigator_full_name>Angela Gurrado</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Dietary Supplements</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Postoperative edema</keyword>
  <keyword>Postoperative collections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresthesia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

